Cargando…

SGLT2 inhibitors improve kidney function and morphology by regulating renal metabolic reprogramming in mice with diabetic kidney disease

Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease (ESRD) worldwide. SGLT2 inhibitors are clinically effective in halting DKD progression. However, the underlying mechanisms remain unclear. The serum and kidneys of mice with DKD were analyzed using liquid chromatography wi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lu, Yong-Ping, Zhang, Ze-Yu, Wu, Hong-Wei, Fang, Li-Jing, Hu, Bo, Tang, Chun, Zhang, Yi-Qing, Yin, Lianghong, Tang, Dong-E., Zheng, Zhi-Hua, Zhu, Ting, Dai, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9476562/ https://www.ncbi.nlm.nih.gov/pubmed/36104729 http://dx.doi.org/10.1186/s12967-022-03629-8

Ejemplares similares

Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease
por: Dai, Zhi-Cheng, et al.
Publicado: (2023)

Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
por: Bailey, Clifford J., et al.
Publicado: (2022)

Antioxidant Roles of SGLT2 Inhibitors in the Kidney
por: Llorens-Cebrià, Carmen, et al.
Publicado: (2022)

SGLT2 Inhibitors and Kidney Outcomes in Patients with Chronic Kidney Disease
por: Kanduri, Swetha R., et al.
Publicado: (2020)

EMPA-KIDNEY: expanding the range of kidney protection by SGLT2 inhibitors
por: Fernández-Fernandez, Beatriz, et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors on Renal Outcomes in Patients With Chronic Kidney Disease: A Meta-Analysis
por: Li, Ning, et al.
Publicado: (2021)

Anthocyanin improves kidney function in diabetic kidney disease by regulating amino acid metabolism
por: Li, Yi-Xi, et al.
Publicado: (2022)

Cardiorenal protection of SGLT2 inhibitors—Perspectives from metabolic reprogramming
por: Gao, Yue-Ming, et al.
Publicado: (2022)

Is There a Diabetes–Kidney–Heart Continuum? Perspectives From the Results of the Cardiovascular and Renal Outcome Clinical Trials With SGLT2 Inhibitors
por: Bao, Liwen, et al.
Publicado: (2021)

The role of microbial metabolites in diabetic kidney disease
por: Zhu, Ting, et al.
Publicado: (2023)

Urinary microbiota and serum metabolite analysis in patients with diabetic kidney disease
por: Yang, Yan, et al.
Publicado: (2023)

A Quantitative Systems Pharmacology Kidney Model of Diabetes Associated Renal Hyperfiltration and the Effects of SGLT Inhibitors
por: Balazki, Pavel, et al.
Publicado: (2018)

SGLT2 Inhibitors in Diabetic and Non-Diabetic Chronic Kidney Disease
por: Podestà, Manuel Alfredo, et al.
Publicado: (2023)

The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
por: Matthews, Jennifer, et al.
Publicado: (2023)

Optimal use of SGLT2 inhibitors in diabetic kidney transplant recipients
por: Pham, Phuong-Thu T., et al.
Publicado: (2022)

Renal effects of SGLT2 inhibitors in cardiovascular patients with and without chronic kidney disease: focus on heart failure and renal outcomes
por: Gronda, Edoardo G., et al.
Publicado: (2022)

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury
por: Aroor, Annayya R., et al.
Publicado: (2018)

Regulation of SARS CoV-2 host factors in the kidney and heart in rats with 5/6 nephrectomy—effects of salt, ARB, DPP4 inhibitor and SGLT2 blocker
por: Xiong, Yingquan, et al.
Publicado: (2022)

A real-world study on SGLT2 inhibitors and diabetic kidney disease progression
por: Liu, Allen Yan Lun, et al.
Publicado: (2022)

A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment
por: Jiang, Zhongji, et al.
Publicado: (2022)

SGLT2 Inhibitors in Chronic Kidney Disease: From Mechanisms to Clinical Practice
por: Skrabic, Roko, et al.
Publicado: (2022)

Digging deep into cells to find mechanisms of kidney protection by SGLT2 inhibitors
por: Tuttle, Katherine R.
Publicado: (2023)

Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
por: Chen, Xiutian, et al.
Publicado: (2023)

NFE2L3 as a Potential Functional Gene Regulating Immune Microenvironment in Human Kidney Cancer
por: Zhang, Qian, et al.
Publicado: (2022)

New Diabetes Therapies and Diabetic Kidney Disease Progression: the Role of SGLT-2 Inhibitors
por: Dekkers, Claire C. J., et al.
Publicado: (2018)

Acute Kidney Injury in Patients on SGLT2 Inhibitors: A Propensity-Matched Analysis
por: Nadkarni, Girish N., et al.
Publicado: (2017)

SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2017)

SGLT2 Inhibitors: Slowing of Chronic Kidney Disease Progression in Type 2 Diabetes
por: Wheeler, David C., et al.
Publicado: (2020)

Chronic Kidney Disease and SGLT2 Inhibitors: A Review of the Evolving Treatment Landscape
por: Mende, Christian W.
Publicado: (2021)

Can SGLT2 inhibitors answer unmet therapeutic needs in chronic kidney disease?
por: De Nicola, Luca, et al.
Publicado: (2022)

SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
por: Rolek, Bartosz, et al.
Publicado: (2023)

Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis
por: Menne, Jan, et al.
Publicado: (2019)

The novel m6A writer METTL5 as prognostic biomarker probably associating with the regulation of immune microenvironment in kidney cancer
por: Wei Zhang, et al.
Publicado: (2022)

Vitamin D-VDR (vitamin D receptor) alleviates glucose metabolism reprogramming in lipopolysaccharide-induced acute kidney injury
por: Dai, Qing, et al.
Publicado: (2023)

Association of SGLT2 inhibitors with cardiovascular, kidney, and safety outcomes among patients with diabetic kidney disease: a meta-analysis
por: Kaze, Arnaud D., et al.
Publicado: (2022)

Correction to: SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease
por: Zou, Honghong, et al.
Publicado: (2018)

2232: Acute kidney injury in patients on SGLT-2 inhibitors: A propensity matched analysis
por: Ferrandino, Rocco, et al.
Publicado: (2018)

Barriers to initiating SGLT2 inhibitors in diabetic kidney disease: a real-world study
por: Jeong, Su Jin, et al.
Publicado: (2021)

Efficacy and Safety of SGLT2 Inhibitors in Diabetic Kidney Transplant Patients: Review of the Current Literature
por: Shuster, Shirley, et al.
Publicado: (2021)

SGLT2 Inhibitors in Patients with Chronic Kidney Disease and Heart Disease: A Literature Review
por: Kansara, Abhishek, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5keu0no6fgf63jjl0j9qcjq993